Home › Kanser ng Endometrium › Tennessee › Nashville
Pag-aaral pangklinika para sa Kanser ng Endometrium sa Nashville, TN
Isang pag-aaral para sa Kanser ng Endometrium ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Nashville. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Nagre-recruitPhase 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin · 17 mi ang layo
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Nagre-recruitPhase 2
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Tennessee Oncology, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI), Nashville
DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
- Research Site, Nashville
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Research Site, Nashville
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Nagre-recruitPhase 2
- Research Site, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institue, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon - Tennessee Oncology, Nashville
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Nagre-recruitPhase 1/2
- Sarah Cannon Nashville, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- GSK Investigational Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Nagre-recruitPhase 1
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1
- SCRI Oncology Partners - Nashville, Nashville
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Nagre-recruitPhase 1
- Normunity Investigational Site, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Nagre-recruitPhase 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
A Study of LY4175408 in Participants With Advanced Cancer
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Tennessee Oncology, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Nagre-recruitPhase 1/2
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Pag-aaral para sa Kanser ng Endometrium sa ibang lungsod
- Houston, TX68 pag-aaral
- New York City, NY52 pag-aaral
- Boston, MA50 pag-aaral
- Arlington, VA39 pag-aaral
- Los Angeles, CA34 pag-aaral
- St. Louis, MO29 pag-aaral
- Philadelphia, PA28 pag-aaral
- San Antonio, TX27 pag-aaral
- Columbus, OH25 pag-aaral
- Oklahoma City, OK25 pag-aaral
- Chicago, IL25 pag-aaral
- Queens, NY25 pag-aaral
Iba pang pag-aaral sa Nashville
- Non-Small Cell Lung Cancer97 pag-aaral
- Kanser sa Suso81 pag-aaral
- Metastatic Cancer70 pag-aaral
- Colorectal Cancer69 pag-aaral
- Kanser (lahat ng uri)65 pag-aaral
- Kanser sa Ovary49 pag-aaral
- Kanser sa Prostate43 pag-aaral
- Kanser sa Baga40 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg39 pag-aaral
- Kanser sa Pancreas39 pag-aaral
- Melanoma33 pag-aaral
- Multiple Myeloma32 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.